论文部分内容阅读
目的比较分析双时相门冬胰岛素30与预混人胰岛素30R在2型糖尿病的临床治疗效果及安全性。方法选择口服药物降糖效果差的2型糖尿病患者68例作为研究对象,随机分为双时相门冬胰岛素组34例与预混人胰岛素组34例,观察两组别的临床疗效、日均胰岛素用量及低血糖的发生率。结果双时相门冬胰岛素组、预混人胰岛素组治疗前后的FBG、2hPBG、HbA1c经t检验分析,统计学差异均有统计学意义(P<0.001);两组别间治疗后FBG、2hPBG、HbA1c经t检验分析均差异有统计学意义(P<0.05)。两组别的日均胰岛素用量、低血糖的发生次数经t检验分析,差异有统计学意义(P<0.05)。结论双时相门冬胰岛素30相对预混人胰岛素30R速效,日均胰岛素用量比较少,低血糖发生率较少,安全性高。
Objective To compare the clinical efficacy and safety of double-phase aspart insulin 30 and pre-mixed insulin 30R in type 2 diabetes mellitus. Methods Sixty-eight type 2 diabetic patients with poor hypoglycemic effect of oral medication were selected as study subjects and were randomly divided into 34 patients with biphasic aspart insulin group and 34 patients with premixed insulin group. The clinical efficacy, The amount of insulin and the incidence of hypoglycemia. Results The FBG, 2hPBG and HbA1c in the double-phase aspart insulin group and the pre-mixed insulin group before and after treatment were significantly different (P <0.001) by t-test. FBG, 2hPBG , HbA1c by t test analysis were statistically significant differences (P <0.05). The average daily insulin dosage and the incidence of hypoglycemia in both groups were analyzed by t-test, the difference was statistically significant (P <0.05). Conclusions Double-phase aspart-insulin 30 is faster than pre-mixed insulin 30R, with less daily insulin dosage, less hypoglycemia, and higher safety.